Instrument Inactif

Autres langues Celsion Corporation Nasdaq

Actions

US15117N3052

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

30/07	IMUNON fait état d'une forte dynamique de recrutement pour l'essai de phase 3 OVATION 3 sur l'IMNN-001 dans le cancer de l'ovaire avancé	CI
30/07	Imunon : recrutement supérieur aux attentes pour l'essai de phase 3 de l'IMNN-001 dans le cancer de l'ovaire	MT

Autres langues

30/07	IMUNON Reports Strong Enrollment Momentum In Phase 3 OVATION 3 Trial Of IMNN-001 In Advanced Ovarian Cancer
30/07	Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer
30/07	IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
23/07	IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
21/07	Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response
21/07	IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
30/06	Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026
30/06	Imunon, Inc. Announces Chief Financial Officer Changes, Effective July 1, 2026
23/06	IMUNON Inc. Continues Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Chemotherapy
23/06	Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue
23/06	IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
22/06	IMUNON to Present at the Life Sciences Investor Forum on June 25th
04/06	IMUNON Announces Up to $10 Million Cash Financing
03/06	Imunon, Inc. announced that it has received $10 million in funding
02/06	Imunon, Inc. announced that it expects to receive $10 million in funding
12/05	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
12/05	Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
31/03	Imunon reports 2025 financial results and provides business update
31/03	Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03	Imunon, Inc. Auditor Raises 'Going Concern' Doubt
25/03	Imunon Inc Reports Updated Phase 2 Data Showing Continued Improvement In Median Overall Survival With IMNN-001 In Women With Newly Diagnosed Advanced Ovarian Cancer
25/03	IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
24/03	IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026